Barclays’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q1 | – | Sell |
-113,490
| Closed | -$2.04M | – | 7609 |
|
|
2017
Q4 | $2.04M | Buy |
113,490
+93,313
| +462% | +$1.15M | ﹤0.01% | 2409 |
|
|
2017
Q3 | $239K | Buy |
20,177
+10,597
| +111% | +$119K | ﹤0.01% | 4280 |
|
|
2017
Q2 | $101K | Sell |
9,580
-12,102
| -56% | -$123K | ﹤0.01% | 4905 |
|
|
2017
Q1 | $238K | Sell |
21,682
-55,503
| -72% | -$644K | ﹤0.01% | 4142 |
|
|
2016
Q4 | $1.05M | Buy |
77,185
+76,727
| +16,753% | +$1.07M | ﹤0.01% | 2694 |
|
|
2016
Q3 | $6K | Sell |
458
-142
| -24% | -$1.67K | ﹤0.01% | 5978 |
|
|
2016
Q2 | $7K | Sell |
600
-6,441
| -91% | -$72.1K | ﹤0.01% | 5676 |
|
|
2016
Q1 | $70K | Buy |
7,041
+611
| +10% | +$7.72K | ﹤0.01% | 4596 |
|
|
2015
Q4 | $109K | Sell |
6,430
-8,008
| -55% | -$144K | ﹤0.01% | 4355 |
|
|
2015
Q3 | $274K | Buy |
14,438
+9,294
| +181% | +$213K | ﹤0.01% | 3884 |
|
|
2015
Q2 | $83K | Buy |
5,144
+4,071
| +379% | +$70.6K | ﹤0.01% | 4802 |
|
|
2015
Q1 | $16K | Sell |
1,073
-3,167
| -75% | -$49.1K | ﹤0.01% | 5970 |
|
|
2014
Q4 | $60K | Sell |
4,240
-1,473
| -26% | -$15.6K | ﹤0.01% | 5581 |
|
|
2014
Q3 | $34K | Sell |
5,713
-5,364
| -48% | -$35.6K | ﹤0.01% | 6168 |
|
|
2014
Q2 | $67K | Buy |
11,077
+697
| +7% | +$4.93K | ﹤0.01% | 5748 |
|
|
2014
Q1 | $72K | Buy |
10,380
+5,948
| +134% | +$50.9K | ﹤0.01% | 5705 |
|
|
2013
Q4 | $39K | Sell |
4,432
-768
| -15% | -$5.48K | ﹤0.01% | 6362 |
|
|
2013
Q3 | $31K | Buy |
5,200
+3,949
| +316% | +$24.7K | ﹤0.01% | 6327 |
|
|
2013
Q2 | $9K | Buy |
+1,251
| New | +$9.93K | ﹤0.01% | 7191 |
|
Other funds holding SCMP
Barclays's SCMP Position: Q1 2018 in Review
Barclays sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q1 2018, closing a stake of 113,490 shares — an estimated $2.04M sold.
Barclays first reported a position in SCMP in Q2 2013 and held it in 19 quarters. The position peaked at $2.04M in Q4 2017. 3 funds tracked by Wall St. Rank hold SCMP as of Q1 2018.
- Barclays reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q1 2018 after selling out during the quarter.
- Barclays sold 113,490 Sucampo Pharmaceuticals, Inc. shares in Q1 2018, an estimated $2.04M.
- Barclays first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2013 and held it in 19 quarters.
- Barclays's Sucampo Pharmaceuticals, Inc. position peaked at $2.04M in Q4 2017.
- 3 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q1 2018.
Based on Barclays's 13F filing for Q1 2018, filed 15 May 2018.